Loading Events
This event has passed.
This event has been cancelled.

Time Slot

Registration

Time Slot

Introduction

Time Slot

Novel Approaches to cfDNA Biomarkers that Do Not Require Sequencing for Mutations
Nic Dracopoli, Ph.D. (Chief Scientific Officer, Delfi Diagnostics)

Time Slot

Insights into Association of Cancer Cachexia and Catabolic Clearance with Response Gained from Pembrolizumab Exposure-Response Assessments
Julie Stone, Ph.D. (Scientific AVP, Dept. of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc.)

Time Slot

Challenges and Strategies in LC-MS/MS Bioanalysis of PD-1 and PD-L1 as Clinical Biomarkers in Formalin Fixed Paraffin Embedded (FFPE) Tissues for Cancer Immunotherapy Development
Naiyu Zheng, Ph.D. (Senior Principal Scientist, Department of Translational Medicine, Bristol-Myers Squibb Company, Princeton, NJ)

Time Slot

Amantadine as a Biomarker Drug for Detection and Therapeutic Monitoring of Cancer
Donald Miller, Ph.D. (Professor, Department of Pharmacology & Therapeutics, Kleysen Institute for Advanced Medicine, University of Manitoba)

Time Slot

Metabolomics, Biomarkers, and Cancer
David Wishart, Ph.D. (Professor, Departments of Biological Sciences and Computing Science, University of Alberta)

Time Slot

The Role for Comprehensive Genomic Profiling in Clinical Studies
Tim Burn, Ph.D. (VP, Translational Research, Incyte Corporation)

Time Slot

Reevaluation of Using the Mental and Physical Test Scores to Determine the Extent of Mercury Toxicity ā€“ Monitoring Test Scores Using the Chelation Agent N,Nā€™-Bis-(2-mercaptoethyl) Isophthalamide
Chris Kemper, Ph.D. (PK/PD/Bioanalytical Consulting, Pharma Navigators, LLC)